Global pharmaceutical company Lupin has announced the carve-out of its consumer healthcare business, LupinLife Consumer Healthcare (LCH), into a wholly owned subsidiary, effective from July 1, 2025. The move is intended to create a focused consumer healthcare entity, aligned with the company’s strategy to address India’s growing self-care and over-the-counter (OTC) market.
LCH was launched in 2017 and has since developed a portfolio of OTC brands including Softovac, Beplex Forte, Corcium, and Aptivate. The newly formed entity will operate independently under the leadership of Anil V Kaushal as Chief Executive Officer. The restructuring is expected to enable targeted investment, increased consumer outreach, market expansion, and growth.
Speaking on the announcement, Nilesh Gupta, Managing Director, Lupin, said, “This strategic move reinforces our mission of developing high-impact businesses that drive sustained value. LCH exemplifies our unwavering dedication to patient-centric care and service to consumers.”
Anil V Kaushal, CEO, LupinLife Consumer Healthcare, added, “This carve-out marks an exciting new chapter in our consumer healthcare journey. We are committed to offering world-class OTC products and wellness solutions for Indian consumers. LCH is well-positioned to scale with agility, innovate with intent, and expand access to wellness solutions across India.”
The announcement underscores Lupin’s intention to strengthen its presence in India’s consumer healthcare segment by creating a dedicated unit for OTC products and wellness services.
The post Lupin carves out consumer healthcare business into wholly owned subsidiary appeared first on Express Healthcare.
